Cultrex® Basement Membrane Matrix, Type 3
Cultrex® BME Type 3 is a Basement Membrane Matrix that has been developed, produced and qualified specifically for use in in vivo studies. BME Type 3 is an extracellular matrix hydrogel that helps cells to adapt to in vivo transplantation. BME Type 3 mimics the in vivo microenvironment, including low glucose and low pH, to improve take rate and growth of implanted cells for xenograft and tumorgraft models.
Description
Cultrex® Basement Membrane Extract (BME) is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumor. This extract provides a natural extracellular matrix hydrogel that polymerizes at 37°C to form a reconstituted basement membrane. Basement membranes are continuous sheets of specialized extracellular matrix that form an interface between endothelial, epithelial, muscle, or neuronal cells and their adjacent stroma and that play an essential role in tissue organization by influencing cell adhesion, migration, proliferation, and differentiation. The major components of BME include laminin, collagen IV, entactin, and heparan sulfate proteoglycans.
Cultrex® BME Type 3 is physiologically aligned with the in vivo environment and is recommended for xenografts, tumorgrafts, and other in vivo applications.
Quality control specifications:
- Mouse colonies are routinely screened for pathogens using mouse antibody production (MAP) testing.
- Engelbreth-Holm-Swarm (EHS) tumor is LDEV-free.
- PathClear® – tested negative by PCR for 17 bacterial and virus strains typically included in mouse antibody production (MAP) testing, plus 13 additional murine infectious agents including LDEV, for a total of 31 organisms and viruses.
- No bacterial or fungal growth detected after incubation at 37°C for 14 days following USP sterility testing guidelines.
- Endotoxin concentration ≤ 8 EU/ml by Limulus Amoebocyte Lysate (LAL) assay.
- Protein concentration of 12 – 18 mg/ml.
- No mycoplasma contamination detected by PCR.
- Provided in Roswell Park Memorial Instituted (RPMI) medium with 10 µg/ml gentamycin.
- Gel stability tested for a period of 14 days at 37°C.
- Biological activity determined for each lot:
- Tumor Growth Assay – BME Type 3 supports proliferation and growth of breast cancer cells (MCF7) embedded in the matrix for minimum of 8 days.
温馨提示:不可用于临床ZL。
资料下载:
protocol_3632-005-02.pdf
附件下载 (下载 1 次)
请 [登录] 后再下载!